Tirzepatide for Skin: What the Evidence Shows
What human and animal studies show about Tirzepatide for skin, how strong that evidence is, and what is still unproven.
- Strongest evidence
- None graded
- no study with an outcome for skin (PubMed search, 2 Oct 2026)
- Human studies
- None found
- with an outcome for skin, in our evidence file (PubMed search, 2 Oct 2026)
- Animal studies
- None found
- with an outcome for skin, in our evidence file (PubMed search, 2 Oct 2026)
Evidence for skin
None of the study abstracts we summarised for Tirzepatide reported an outcome for skin (PubMed search, 2 Oct 2026). Claims that it helps with skin are unproven.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Skin: psoriasis, hair and appearance
MedlinePlus says psoriasis is a skin disease causing itchy or sore patches of thick, red skin with silvery scales, and that a problem with the immune system causes it.[16]
One trial, TOGETHER-PsA, bears on skin: in people with psoriatic arthritis and overweight or obesity, adding tirzepatide to ixekizumab produced nominally better PASI skin scores than ixekizumab alone.[17]
That was a combination, a secondary end point, and a nominal result, so it is not a test of tirzepatide for psoriasis or eczema alone.[17]
Hair loss and 'Ozempic face'
The Zepbound label reports hair loss associated with weight reduction, 7.1% in women against 0.5% in men on the drug, versus 1.3% and 0% on placebo.[18]
No treated patient stopped the drug because of hair loss, but one placebo patient did, according to the same label passage.[18]
A recent narrative review says rapid large weight loss on these drugs drives soft-tissue changes called 'Ozempic face' and 'Ozempic body' with accelerated skin laxity, which is a review's description, not a measured trial outcome.[19]
Other peptides people research for skin
All peptides for skin, comparedCommon questions
Does Tirzepatide help with skin?
None of the studies we summarised for Tirzepatide (PubMed search, 2 Oct 2026) measured an outcome for skin. Treat claims that it helps with skin as unproven.
Is Tirzepatide approved for skin?
Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for skin?
There is no single answer. Our skin overview compares each candidate by evidence grade and legal status rather than by popularity.
Does tirzepatide help psoriasis?
Only in combination: with ixekizumab it showed nominal PASI improvements in psoriatic arthritis versus ixekizumab alone.[17]
Does tirzepatide cause hair loss?
The label reports hair loss associated with weight reduction, more often in women, at 7.1% on the drug versus 1.3% on placebo.[18]
Does tirzepatide cause loose skin?
A review describes accelerated skin laxity with rapid large weight loss on obesity drugs, but no trial quantified it for tirzepatide.[19]
More on Tirzepatide
Sources
- 1PubMed search: tirzepatide[ti] AND (SURMOUNT[tiab] OR SURPASS[tiab]) AND randomized controlled trial[pt] (93 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-4 OR SURPASS-5 OR "versus semaglutide" OR "SURPASS-CVOT" OR dulaglutide) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: tirzepatide[ti] AND (steatohepatitis OR NASH OR "heart failure" OR HFpEF OR "preserved ejection" OR cardiovascular) (410 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-1 OR SURPASS-5 OR "SURPASS J-mono") AND randomized controlled trial[pt] (24 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: tirzepatide[ti] AND (steatohepatitis OR "heart failure" OR "SUMMIT" OR "SYNERGY-NASH" OR "phase 2") AND randomized controlled trial[pt] (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: tirzepatide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR glycemic OR HbA1c OR obesity) (178 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: tirzepatide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (49 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: tirzepatide[ti] AND (insulin degludec OR "SURPASS-3") AND "type 2 diabetes"[ti] AND randomized controlled trial[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: tirzepatide[ti] AND (cardiovascular outcomes OR "SURPASS-CVOT" OR "major adverse") (228 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: tirzepatide[tiab] AND (depression OR anxiety OR ADHD OR osteoporosis OR "bone mineral" OR menopause OR "rheumatoid" OR arthritis OR testosterone) (121 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: tirzepatide[tiab] AND ("body composition"[tiab] OR "lean mass"[tiab] OR "visceral fat"[tiab] OR "fat mass"[tiab]) AND humans[mh] (91 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: tirzepatide[tiab] AND (blood pressure[tiab] OR cholesterol[tiab] OR lipid*[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: tirzepatide[tiab] AND (SURPASS-CVOT OR "cardiovascular events" ) AND "dulaglutide"[tiab] AND randomized controlled trial[pt] (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: tirzepatide[tiab] AND (depression[tiab] OR anxiety[tiab] OR "mental health"[tiab] OR ADHD[tiab] OR "binge eating"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: tirzepatide[tiab] AND (menopaus*[tiab] OR PCOS[tiab] OR "polycystic"[tiab] OR testosterone[tiab] OR hypogonadism[tiab]) (55 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Official web pageOfficial web page · web page
- 17Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 19Anti-Obesity Medications in Longevity and Aesthetic Medicine.Journal of clinical medicine · 2026PMID 42590128Accessed 2 Oct 2026
Found an error? Report a correction.